Oncology
At Johnson & Johnson, our focus is singular—eliminate cancer.
We listen and learn with compassion to understand the needs of patients, caregivers and healthcare professionals who remind us every day why we are working toward this bold ambition.
Cancer remains a leading cause of death globally. In 2022 alone, 20 million people worldwide were diagnosed with cancer, and almost 10 million died of the disease. With more than a three-decade legacy in oncology innovation, our commitment to pioneer new therapeutic advances for patients with cancer has never been stronger.
Expand
Collapse
Cancer remains a leading cause of death globally. In 2022 alone, 20 million people worldwide were diagnosed with cancer, and almost 10 million died of the disease. With more than a three-decade legacy in oncology innovation, our commitment to pioneer new therapeutic advances for patients with cancer has never been stronger.
Disease areas
Innovation
-
Interventional oncology
Johnson & Johnson is advancing intratumoral treatments—therapies delivered directly into tumors—by integrating our unique Innovative Medicine and MedTech expertise. Learn more.
-
Data science & AI
From target discovery and patient segmentation to drug design and chemistry, manufacturing and controls process optimization, J&J uses data science and AI to accelerate all facets of clinical development. -
Global Centers of Excellence (COE)
COEs include biomarkers, companion diagnostics, biologics, and precision medicine, which are further enhanced by local expertise in regulatory and medical affairs.
Learn more
Check out our pipeline
Our robust pipeline spans multiple focus areas with a number of programs in development, as well as select novel therapy programs recently approved, or with potential filings in the United States/European Union.
Read more
You are now leaving jnj.com
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
You are now leaving jnj.com
This link will take you to a website outside of Johnson & Johnson, which is governed by its own privacy policy and terms of use.
Read our brochure
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Resources
Johnson & Johnson: In front of cancer
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Early intervention: How Johnson & Johnson researchers are working to help patients at risk of developing multiple myeloma
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Meet two brothers who are revolutionizing the way scientists develop treatments for cancer
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Using your own cells to fight cancer
Cell therapy is bringing the world one step closer to eliminating cancer. Here’s how Johnson & Johnson has treated more than 10,000 patients and counting with this cutting-edge therapy.
Inside the development of a revolutionary treatment for blood cancers
In 2014, a Johnson & Johnson therapy gained approval for the treatment of a type of B-cell malignancy—increasing survival rates and changing the way scientists approach cancer treatment. These 8 milestone moments tell the transformational story.
